Noninvasive preimplantation genetic testing for aneuploidy in spent blastocyst media will substitute for trophectoderm biopsy

The discovery of cell-free fetal deoxyribonucleic acid in maternal plasma has enabled a paradigm shift in prenatal testing (1). Since its inception, noninvasive prenatal testing (niPGT) has dramatically changed clinical practice in prenatal care, allowing safer and earlier detection of genetic conditions of the fetus during the first trimester of pregnancy (2). In our subspecialty, the current practice for preimplantation genetic testing for aneuploidies (PGT-A) requires embryo manipulation, specifically trophectoderm (TE) biopsy, with the retrieval of 4-8 cells and analysis of chromosome copy number using next-generation sequencing (3). However, biopsy-based approaches for preimplantation embryos entail both technical and embryo viability challenges together with the criticism that in some cases, normal embryos may be discarded